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Effect of corneal epithelium on ultraviolet-A and riboflavin absorption
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INTRODUCTION
Corneal collagen cross-linking (CXL) has been described as a
promising therapy for keratoconus and post-refractive surgery
keratectasia(1,2). Previous studies(3-7) have shown that riboflavin/ultra-
violet-A (UVA) treatment leads to an increase in the biomechanical
stabilization and stiffness of the cornea. It is already known that
corneal tissue from keratoconus eyes are biomechanically weake-
ned compared to normal corneas(8). This minimally invasive pro-
cedure treats and prevents the underlying pathophysiological cau-
se of cornea ectasia as it attempts to modify the inadequate me-
chanical stability of these corneas.
RESUMO
Objetivo: Determinar se o epitélio corneano pode impedir ou diminuir o efeito do trata-
mento com “cross-linking” (CXL). Por meio  de microscopia por imunofluorescência, foi
indiretamente analisado o efeito do epitélio como escudo aos raios ultravioleta-A (UVA),
assim como barreia à penetração da riboflavina.
Métodos: Quinze olhos enucleados de porcos foram divididos em 3 grupos. O epitélio
corneano foi mantido intacto em todos os grupos. Cinco olhos serviram como controle
(Grupo 1). No grupo 2, os olhos foram instilados com colírio anestésico de tetracaína,
assim como colírio de riboflavina 0,1% (10 mg de riboflavina-5-fosfato em 10 ml de
dextran 20% T-500). No grupo 3, solução de riboflavina foi injetada na câmara anterior
para permitir a penetração da droga através do endotélio. Os grupos 2 e 3 foram então
expostos à radiação UVA (365 nm, 3 mW/cm2) por 30 minutos. Subsequentemente,
cortes ultrafinos (8 μm) das córneas foram marcados com anticolágeno tipo I e DAPI
(4,6-diamidino-2-fenilindole dihydrocloride) e analisados com microscópio de
imunofluorescência.
Resultados: As córneas que receberam injeção intracameral de riboflavina e foram
irradiadas com UVA (Grupo 3) mostraram um padrão maior de organização das fibras
de colágeno em relação aos grupos 1 (Controle) e 2 (instiladas com colírio anestésico e de
riboflavina). Macroscopicamente, a coloração amarelada do estroma, que representa a
difusão da riboflavina, foi apenas observada nos olhos que receberam riboflavina
intracameral.
Conclusão: Foi demonstrado, através de microscopia por imunofluorescência em córneas
de porcos, que o epitélio corneano íntegro diminui a efetividade do CXL por reduzir a
penetração da riboflavina, e não por impedir a penetração dos raios UVA. Uma concen-
tração intraestromal inadequada de riboflavina limita o efeito do tratamento.
Descritores: Reagentes para ligações cruzadas/uso terapêutico; Riboflavina/farmaco-
cinética; Epitélio corneano; Microscopia de imunofluorescência; Agentes fotossensibilizantes;
Raios ultravioleta; Suíno 
ABSTRACT
Purpose: To determine if the corneal epithelium prevents the collagen cross-linking
effect. Using immunofluorescence microscopy after CXL, we indirectly analyzed the
role of the epithelium as ultraviolet-A (UVA) shield as well as a barrier to riboflavin
penetration.
Methods: Fifteen freshly enucleated porcine eyes were divided into 3 groups. The
corneal epithelium was kept intact in all groups. Five eyes served as control (Group 1).
On group 2, eyes received tetracaine anesthetic drops and topical 0.1% riboflavin
solution (10 mg riboflavin-5-phosphate in 10 mL 20% dextran-T-500). On Group 3,
riboflavin was injected into the anterior chamber to allow penetration of the drug
through the endothelium. Groups 2 and 3 were exposed to UVA (365 nm, 3 mW/cm2)
for 30 minutes. Ultra-thin sections (8 μm) of the corneas were stained with anti-
collagen type I and DAPI (4,6-diamidino-2-fenilindole dihydrocloride) and analyzed
with fluorescence microscopy.
Results: Corneas treated with UVA irradiation and intracameral injection of riboflavin
(Group 3) showed greater pattern of collagen organization compared to groups 1
(Control) and 2 (riboflavin and tetracaine eye drops). A yellow stromal staining, which
represents the riboflavin diffusion into the stroma, was only observed in eyes
injected with riboflavin into the anterior chamber.
Conclusion: Using immunofluorescence microscopy in porcine corneas, we demons-
trated that the corneal epithelium reduces the effectiveness of CXL by preventing the
penetration of the drug and not by limiting the UVA transmittance. An inadequate
intrastromal concentration of riboflavin may impair CXL effect.
Keywords: Cross-linking reagents/therapeutic use; Riboflavin/pharmacokinetics; Epi-
thelium, corneal/physiology; Microscopy, immunofluorescence; Photosensitizing
agents; Ultraviolet rays; Swine
The CXL protocol recommended by Wollensak et al.(3) states that
the central epithelium should be debrided before treatment to
allow penetration of riboflavin into the corneal stroma (epi-off
technique). However, removal of the epithelium can increase the
risks of corneal infections, ulcers, haze, scarring and infiltrates, be-
yond longer recovery time, discomfort and postoperative pain
experienced by patients(9-12). Recently, slight modifications of this
technique were proposed to overcome the potential disadvanta-
ges of epithelium removal: one approach advocates the use of
multiple applications of topical anesthetic eye drops to loosen the
tight junctions of the corneal epithelial cells, thus facilitating ribo-
flavin penetration through an intact epithelium(13,14). Others per-
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form a grid-like pattern de-epithelialization instead of complete epi-
thelial removal, attempting to hasten postoperative healing(15). Ano-
ther method allows the stromal diffusion of the riboflavin through a
femtosecond laser-created central corneal pocket(16,17). This pocket
enables for superficial intrastromal administration of riboflavin solu-
tion without de-epithelialization. All of these techniques, however,
have not considered the potential effect of the corneal epithelium as
an UVA filter.
The corneal epithelium plays an important role in the UV absor-
bing processes. Ultraviolet rays can induce production of reactive
oxygen species and cell death in cultured corneal cells. To protect
against these effects, there is a high ascorbate concentration and
anti-oxidant enzymes in the corneal epithelium that absorbs por-
tions of the irradiation, thereby protecting deeper eye structu-
res(18,19). While the integrity of the epithelium can protect the un-
derling structures from UVA penetration, it may act as a barrier, redu-
cing the effects of CXL.
Our group has already suggested that CXL without previous
epithelial debridement has a decreased effect comparing to the
standard epi-off technique(20). However, at that time, we did not
clarify whether this reduced effect was due to an inadequate absorp-
tion of UVA or due to poor penetration of the riboflavin through
the epithelium. To investigate this question, the present study was
conducted to determine if the epithelium, acting as a UV filter,
prevents the CXL effect. The occurrence of CXL in corneas with intact
epithelium was evaluated using immunofluorescence microscopy
of collagen type I.
METHODS
The research was approved and conducted in compliance with
the Declaration of Helsinki and the Federal University of São Paulo
Ethical Committee - Investigational Review Board (CEP 01565/07).
The study was performed on 15 enucleated porcine eyes within
6 hours postmortem from the slaughterhouse. Each specimen un-
derwent slit lamp evaluation. If there was evidence of corneal scar-
ring, opacity or other abnormalities, the specimen was discarded.
The epithelium was not removed in any groups and its anatomical
integrity was assured by slit lamp examination. Eyes were divided
into 3 groups, each one with five porcine eyes:
Group 1 (control - no treatment): no treatment was performed.
Group 2 (riboflavin + tetracaine eye drops): Anesthetic drops of
0.5% tetracaine (to simulate a clinical scenario) and 0.1% riboflavin
eye drops (10 mg riboflavin-5-phosphate in 10 mL dextran T-500
20%) were applied to the anterior corneal surface every 5 minutes,
beginning 30 minutes prior, and continuing during the UVA treat-
ment. One minute interval between anesthetic and riboflavin drops
was given.
Group 3 (riboflavin injected into the anterior chamber): 0.1%
riboflavin solution was injected into the anterior chamber through
a limbal port to allow the endothelial penetration of the drug. UVA
exposure was carried out after 30 minutes of the injection. Our
purpose was to indirectly analyze the role of the epithelium as a
UVA shield in the CXL process.
ULTRAVIOLET-A EXPOSURE
Ultraviolet-A irradiation (365 nm) was applied 45 mm from the
cornea for 30 minutes using a solid-state device (X-Link; Opto
Eletronica, Sao Carlos, Brazil) with a surface irradiance of 3 mW/cm2.
Total radiant exposure to the cornea was 5375 J/cm2. The surface
irradiance was guaranteed by the micro processed, continuous,
self-controlled monitoring system of the device that utilizes an
internal power meter. The UVA source consisted of a homogenized
9 mm beam that uses a capsulated, matrix light emitting diode as
its source.
IMMUNOFLUORESCENCE MICROSCOPY
After dissection with a 9 mm trephine, corneal buttons were
embedded in tissue freezing media (Leica Microsystems Inc., Banno-
ckburn, IL, USA) and immediately frozen at -70°C. Ultra-thin sections
(8 mm) were performed on a cryostat at -21°C.
After washing with phosphate-buffered saline (PBS), the slides
were incubated for 1 hour with the primary antibody anti-type I
collagen 1:500 (Calbiochem, Darmstadt, Germany) in PBS containing
1% bovine serum albumin (BSA) and 0.1% saponin. Afterwards, the
slides were washed in PBS and incubated with anti-mouse IgG se-
condary antibody conjugated with AlexaFluor 488 (Molecular Pro-
bes, Carlsbad, CA, USA) (1:300, 30 min). The slides were washed
and the nuclei were stained using DAPI (4,6-diamidino-2-fenilin-
dole, dihydrocloride - Molecular Probes) 1:1000 in PBS containing
0.1% saponin for 30 minutes. Sections were observed under a
Nikon E800 fluorescence microscope using a B-2E/C filter, 494 nm
wavelength for excitation and 518 nm for emission (Nikon, Melville,
NY, USA).
Images were digitized using a CoolSNAP-Pro charge-coupled
device (CCD) digital camera and Image-Pro Express Software (Media
Cybernetics, Silver Spring, Md., USA). Slides untreated with prima-
ry antibodies were used as negative controls.
RESULTS
Macroscopically, only corneas from group 3 (riboflavin injected
into the anterior chamber) showed a yellow stromal staining, which
represents the riboflavin diffusion into the stroma (Figure 1). Mi-
croscopically, porcine corneas from group 3 showed a greater pat-
tern of collagen organization compared to groups 1 (Control) and 2
(riboflavin + tetracaine eye drops). Interfiber spaces were similarly
displaced on groups 1 and 2, whereas in group 3, the collagen fibers
were more compacted on the anterior portion (Figure 2).
Immunofluorescence analysis using anti-collagen type-I and DAPI
for nuclei was performed to assess the organization of collagen
fibers and epithelium integrity respectively (Figure 2). DAPI was used
to assess the keratocytes and epithelial cells distribution rather
than to analyze apoptosis. The apoptosis reaches its peak after 24
hours. In our study, our samples were immediately submitted to
immunofluorescence microscopy after the experimental procedure.
Therefore, we assume that images suggesting apoptosis would not
be found in the present study. Collagen fibers appeared in green
and were higher organized on group 3 compared to the other
groups. The epithelial cells and keratocytes nuclei could be identi-
fied as blue bodies.
DISCUSSION
The complete removal of the epithelium has been recommen-
ded as an initial step of the CXL procedure since its lipophilic nature
reduces the diffusion of riboflavin into the corneal stroma(20-26). Mo-
reover, the epithelium may block UV rays(27-29). Despite this recom-
mendation, some ophthalmologists have adopted the “epi-on” te-
chnique, with intact epithelium(13,14). This technique, also called
transepithelial CXL, attempts to minimize possible complications
due to epithelial debridement such as corneal ulcer, infections,
haze as well as photophobia, prolonged recovery time and pain.
In the CXL process, the synergism of UVA rays and riboflavin is
crucial(20). It is known that the corneal epithelium strongly absorbs
ultraviolet (UV) radiation due to high amounts of tryptophan resi-
dues and high ascorbate content(28). It protects deeper corneal struc-
tures against UV damage by absorbing a substantial amount of the
irradiation applied to the eye. However, Kolozsvári et al.(29) reported
that the corneal epithelium has a significantly higher absorption
coefficient for UV rays with wavelengths shorter than 300 nm, thus
higher UV waveband, such as 365 nm used in CXL treatment, is
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mainly absorbed by the corneal stroma and lens rather than by the
epithelium. To evaluate the role of the epithelium in the CXL process
as a potential UV filter, we injected riboflavin into the anterior
chamber, bypassing the epithelium. In spite of the lipophilic single
cell layer architecture of the endothelium, the stroma was stained
by the riboflavin (yellow), demonstrating that riboflavin crossed
the endothelium. It is known that the endothelium is permeable to
riboflavin(2,22). This phenomenon is observed during the classic epi-
off treatment by the presence of a yellow flare in the aqueous
humor after instillation of riboflavin. We clearly demonstrated that
corneas injected with riboflavin into the anterior chamber showed
higher organization of the collagen fibers compared to corneas with
intact epithelial basal membrane instilled with riboflavin and te-
tracaine drops. Therefore, although the epithelium can partially
block the UV rays, the amount of UVA that reached the stroma was
sufficient for the occurrence of CXL.
Due to the pharmacological properties (hydrophilia) and its high
molecular weight (376.37 g/mol), riboflavin has a poor penetration
through the epithelium. In 2008, Bottós et al.,(20), demonstrated that
CXL did not occur in porcine eyes with intact epithelium. In their
study, however, riboflavin was instilled alone. Nevertheless, in a clinical
setting riboflavin is instilled with topical anesthetic, which may
increase epithelium permeability by disrupting tight junctions. In
the current study, however, even with the addition of tetracaine
we were still not able to detect CXL. Our results are in accordance
with previous reports. In 2008, Hayes et al.(21) used spectrophoto-
metry to assess the ability of the riboflavin to penetrate the epithe-
lium. They concluded that the presence of an intact epithelial basal
membrane acts as a barrier to riboflavin absorption, which is not
disrupted by trauma nor tetracaine eye drops. Samaras et al.,(15) repor-
ted that the absorption of riboflavin was still not adequate despite
Figure 1. Photographs of corneal buttons, both with intact epithelium. Left cornea: riboflavin was injected into the
anterior chamber. Right cornea: Topical tetracaine and riboflavin drops were instilled on the anterior surface of the cornea.
Figure 2. Immunofluorescence microscopy using anti collagen-I (A, B, C) and corresponding images of fluorescence microscopy for nuclei (DAPI)
(D, E, F). Original magnification X40. A) Control cornea, no treatment was performed. Arrows show the interfiber spaces. B) Group 2: Topical
riboflavin and tetracaine drops were applied. Arrows show the interfiber spaces. C) Group 3: Riboflavin solution was injected into the anterior
chamber. Note the reduced interfiber spaces compared to the other groups.
A B C
D E F
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the aggressive attempt to loosen the epithelial tight junctions with
20% alcohol or the grid-like pattern of de-epithelialization. In a
clinical study, Leccisotti et al.(14) found a limited but favorable effect
of transepithelial CXL in keratoconus eyes. They reported that this
effect appeared to be less pronounced than described in the
literature after CXL with de-epithelialization. Their approach in-
volved the preoperative use of other drugs such as: Ribomicin eye
drops, 0.3% gentamicin, 0.01% EDTA (ethylenediamine tetraacetic
acid), 0.01% benzalkonium chloride and 0.4% oxybuprocaine eye
drops. Since our goal was to follow the standard technique pro-
posed by Wollensak et al.(3) rather than test new modalities of transe-
pithelial CXL, these medications were not tested; therefore, our
results may not be applicable to these transepithelial techniques.
Safety should be carefully analyzed when using riboflavin drops
on an intact epithelium: even though the epithelium may protect
the underlying ocular structures by absorbing some amount of UV
rays (without impeding CXL effect), riboflavin penetration will be
impaired. It is well known that riboflavin is essential to CXL process,
not only by acting as a photosensitizer, but also by preventing the
harmful effects of irradiation(20,22,23). This drug absorbs UVA preven-
ting injuries to deeper ocular structures such as the endothelium,
crystalline lens and retina. Wollensak et al.(7) determined the damage
threshold of the combination of UVA and riboflavin to be 0.35 mW/cm2,
which is 10 times lower than UV alone (4 mW/cm2). However, because
of the riboflavin shielding effect, the clinically applied UV irradiance
at the endothelium level is smaller than the damage threshold. An
adequate amount of riboflavin is of paramount importance because
it has an amplification effect on UVA absorption, thus reducing the
irradiance transmission through the cornea.
Immunofluorescence microscopy was proposed by Bottós et al.(20)
in 2008 as new approach to indirectly visualize the effect of colla-
gen cross-linking, which was later validated by other authors(30).
Bottós et al.(20) addressed the isolated effect of riboflavin on the
collagen organization and corneal dehydration by applying 0,1%
riboflavin solution to de-epithelialized corneas without UVA expo-
sure. It is expected that 20% dextran may cause some stromal
dehydration. Therefore, the analysis of riboflavin solution alone is
important to clarify whether the stromal compaction was due to
dehydration or due to the CXL effect. It was not possible to distin-
guish corneas receiving only riboflavin drops from those of the
control group (without any treatment), meaning that riboflavin
solution alone is not sufficient to cause the same level of collagen
organization than the CXL treatment with riboflavin/UVA in debri-
ded corneas. For this reason, in the present study, we assume that
the high collagen organization observed when riboflavin was in-
jected into the anterior chamber was a result from the CXL affect.
Limitations of this study include the small number of eyes tested
and the use of enucleated porcine corneas instead of human corneas.
Further studies addressing this issue should be performed, using a
larger sample of human eye-bank eyes.
The present study may have significant implications for the de-
velopment of future CXL techniques. As new transepithelial approa-
ches have been proposed, it is important to define which are the
critical steps for CXL effectiveness. Using immunofluorescence mi-
croscopy, we demonstrated that the intact epithelial basal membra-
ne reduces the effect of CXL by preventing the penetration of the
drug and not by limiting the UVA transmittance. Therefore, our
study provides additional evidence that the CXL should be perfor-
med either without the epithelium or by using an efficient method
to deliver riboflavin into corneal stroma.
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